Numeric Biotech is a biopharmaceutical company fully dedicated to cure rare diseases in the field of autoimmune and neuro-degenerative diseases. In particular where chronic (neuro) inflammation is a root cause of the disease.
Our experienced management team is developing first-in-class compounds to eliminate the surplus of senescent cells and to reduce pro-inflammatory cytokines such as IL-6.
Through selectively targeting the foxo4-p53 axis in the nucleus of the senescent cell our compounds will have specific control over the functionality and numbers of regulatory T-cells ( Tregs).
By reducing pro-inflammatory cytokines and increasing Tregs, the compounds have the potential to become the first-in class immunomodulators for the treatment of (neuro)-inflammatory and autoimmune diseases.
Hans van Berkum served as CEO (and was also member of the Board of Directors) of Virosome Biologicals BV. from founding until the company was acquired by Norwood Immunology (now Mymetics Corp.). Prior to that he held several senior executive positions: being responsible for worldwide regulatory affairs of major pharmaceutical companies and was international medical director of US based pharmaceutical company. He was also a European general manager of a main biotech company, running the first approval process of lead compounds and successful introduction and marketing. During his career he was actively involved in various M&A and investment projects. He worked for companies such as Astra (now AstraZeneca), Hoffmann- La Roche, and Genzyme (now Sanofi) in several executive management positions.
Hans obtained a PharmD degree specializing in neuroscience from the University of Leiden (The Netherlands) and holds an International Master of Business Administration from the Dutch School of Management in Utrecht (The Netherlands).
Lars Bastiaanse has over 25 years of experience in clinical development, project management and general management in the pharmaceutical, biotech, and CRO/Consultancy business. He was with Johnson & Johnson in positions of increasing seniority in the product development. Amongst other responsibilities, Lars was Global Project Leader at J&J for the development of immunology products currently on the market such as Intelence, and Edurant. In addition, Lars was CEO for Kinesis Pharma, 3D-PharmXchange, and Cardialysis. Lars is also the General Manager of PMD Consulting BV, an independent life science consultancy organization.
Lars obtained a MSc degree in pharmacy and completed his PhD degree in Medicinal Sciences (cardio biochemistry) at the Leiden University Medical Centre (The Netherlands).
Erik Hack (1952) studied medicine at the University of Amsterdam (The Netherlands) and completed his PhD also in medicine. After his thesis he held several positions in the former Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, now Sanquin Blood Supply Foundation, ranging from principal investigator to head of the Department of Immunopathology. He was appointed as Professor in Immunology at the Free University Medical Center in 1994. Thereafter he became head of the Protein Biologics Group of Crucell (currently part of J&J), in The Netherlands. In 2009 he accepted the position of Professor of Immunology at the University Medical Center in Utrecht (UMCU),founded the Laboratory of Translational Immunology, which harbours all immunology research of the UMCU, and initiated the strategic program on Infection and Immunity. He has assisted to found the Dutch patients association of hereditary and Quincke’s edema. Erik Hack’s research interests are the role of inflammation and coagulation in experimental and human diseases. He has performed a number of clinical and experimental studies on C1-inhibitor in angioedema as well as in other diseases such as sepsis and myocardial infarction, and amongst others has initiated projects on recombinant C1-inhibitor (Ruconest, Pharming Technologies) and plasma-derived C1-inhibitor (Cinryze, now Shire). Both products have been approved by the EMA and the FDA. His current research is on the modulation of inflammatory and coagulation responses in human (neuro-)inflammatory disease with antibodies against key mediators. One of the antibodies discovered by Erik Hack, is an antibody, ArgX-117, now evaluated by ArgenX company in clinical studies. In addition, Erik Hack has co-founded Synerkine Pharma which develops fusion proteins of cytokines for the treatment of inflammatory and immune diseases, as well as of chronic pain. Erik Hack has co-authored over 500 peer-reviewed papers, which have been cited more than 44,000 times (H-index 108, Google Scholar, 28 april 2020). In addition, he has written >20 patents.
Brian Eisenburger brings over 27 years of international operations and project management experience. Having worked in Europe, Japan and the US he gained expertise working in various leadership roles for various bio-pharmaceutical companies but also at CMO/CRO companies. As director business development he was responsible for out-licensing activities at a number of biotech companies, such as Pharming, Algonomics, DSM, etc. He was responsible for various successful venture capital fundraising deals and sales & marketing activities. He set up a branch office in the pharmaceutical industry in Japan for an European CRO organisation, worked as senior production project leader in the US for a worldwide pharmaceutical & food ingredient company. His background education is master of business economics (Erasmus University Medical Center Rotterdam) and engineering (Technical University in Delft, The Netherlands).
Erik Doevendans has 25 years’ industry experience with expertise in drug development and a background in regulatory affairs, quality assurance and manufacturing operations. He served as senior director Regulatory Affairs and manufacturing at Pharming NV where he brought recombinant C1-inhibitor to the market. Notably he was previously a senior pharmaceutical assessor at the Dutch regulatory authorities and an expert to the European Medicines Agency (EMA). Erik has an MSc in Pharmacy from Utrecht University, where he is still involved in the department of Pharmaceutics, with special interest in regulatory science and the relevancy of animal models used in non-clinical development.
Patricia Ringeling is a qualified Dutch and European Patent Attorney. Patricia has more than 20 years of extensive patent experience as a patent attorney in various settings. Previously, Patricia was in-house patent attorney at Gist-Brocades/DSM, Director Intellectual Property at Pharming, and patent attorney at private practice Nederlandsch Octrooibureau (NLO). She works at the independent patent practice Enelex Innovation BV in Delft, which she founded in 2006 to provide patent support to start-ups and innovative SMEs in the life sciences. Patricia is a member of the Institute of Dutch Patent Attorneys, the Institute of Professional Representatives before the European Patent Office, Licensing Executive Society (LES) and Public interest Intellectual Property Advisors (PIIPA), a global non-profit resource for public interest organizations in developing countries seeking expertise in intellectual property.
Patricia studied chemistry with minors immunology and oncology, at the University of Amsterdam and holds a PhD from the Erasmus University Medical Center (The Netherlands). She was as a postdoc researcher in the field of iron metabolism at the University of East Anglia, Norwich UK, and a lecturer in bioinorganic chemistry. Patricia holds a Certificate in Intellectual Property from Queen Mary, University of London.
Throughout his career, Jarek increasingly focused on peptide and small molecule drug discovery and optimization. With a track record of introducing practical solutions to difficult drug discovery problems, he brings a wealth of experience and an unbiased attitude to the company. Jarek joined Janssen Pharmaceutical in 2010 and is now a Principal Scientist at the company. At Janssen, he works in the field of infectious and neurodegenerative (Alzheimer’s) diseases, focusing on both therapeutic and preventative approaches. He has an extensive experience in molecular design and discovery of peptidic compounds based on antibody structures, including cyclic and D-peptides. In his previous job at the Spanish National Cancer Research Center (CNIO), Madrid, Spain, Jarek focused on improving computational methodologies in cancer drug discovery using the example of CDK2 inhibitors and helped develop an allosteric inhibitor of FGFR2 signaling in collaboration with Sanofi Aventis. Jarek’s research has been internationally recognized in more than 20 publications, with several appearing in high impact journals including Science.
Jarek obtained his PhD from the University of Amsterdam (The Netherlands) in computational biophysics.